ENGN
name pending profile ingest
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 22 | -4 | 8.16M | $14.12M | +4 | −8 |
| Q1 2026 | 26 | +4 | 5.29M | $36.02M | +6 | −2 |
| Q4 2025 | 22 | +2 | 7.05M | $63.63M | +3 | −1 |
| Q3 2025 | 8 | -1 | 3.24M | $22.15M | n/a | −1 |
| Q2 2025 | 7 | +2 | 2.63M | $9.57M | +3 | −1 |
| Q1 2025 | 5 | 0 | 3.20M | $14.35M | n/a | n/a |
| Q4 2024 | 5 | 0 | 3.41M | $22.70M | n/a | n/a |
| Q3 2024 | 5 | 0 | 3.74M | $24.69M | +1 | −1 |
| Q2 2024 | 5 | n/a | 4.75M | $44.79M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Adage Capital Partners ✦ | 3.30M | n/a | $31.12M | 0.1% | n/c | 1 | SEC ↗ |
| 2 | Marshall Wace ✦ | 764.64K | n/a | $7.21M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | Citadel Advisors ✦ | 613.29K | n/a | $5.78M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | Point72 Asset Management ✦ | 43.90K | n/a | $413,977 | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 27.52K | n/a | $259,475 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 2 holders, 343.96K shares, $2.34M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Officer, Director · Interim Chief Medical… · 5.10K sh @ 1.97 · $10,051
Open-market sales (S)
No open-market insider sales in our coverage window.
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology